Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы», Москва, Россия; 2 ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия omekan@mail.ru
Список исп. литературыСкрыть список 1. Otify M, Laios A, Elshamy T, D’Angelo A, Amso NN. A systematic review and meta-analysis of the use of ultrasound to diagnose borderline ovarian tumours. Eur J Obstet Gynecol Reprod Biol. 2020;244:120-7. DOI: 10.1016/j.ejogrb.2019.11.016 2. Rasmussen CB, Kjaer SK, Albieri V et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case-control studies. Am J Epidemiol. 2017;26(1):104-9. 3. RH. Young Ovarian tumors: a survey of selected advances of note during the life of this journal. Hum Pathol. 2020;95:169-206. 4. Boyraz G, Salman MC, Gultekin M et al. What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case-control study. Arch Gynecol Obstet. 2017;296:979-87. 5. Kurman RJ, Carcangiu ML, Herrington CS, Young RH et al. WHO classification of tumours of female reproductive organs. 4th ed. France International Agency for Research on Cancer. Lyon: IARC Press, 2014. 6. Sun Y, Xu J, Jia X. The diagnosis, treatment, prognosis and molecular pathology of borderline ovarian tumors: current status and perspectives. Cancer Manag Res. 2020;12:3651-9. DOI: 10.2147/cmar. s250394 7. Crane EK, Thaker PH. Borderline tumors of the ovary. In: Textbook of uncommon cancer. Eds. D. Raghavan, M.S. Ahluwalia, Ch.D. Blanke et al. 5th ed. Wiley Blackwel, 2017. P. 572–81. 8. Maramai M, Barra F, Menada MV et al. Borderline ovarian tumours: management in the era of fertility-sparing surgery. Ecancermedicalscience. 2020;14:1031. 9. Nayyar N. Lakhwani P, Goel A et al. Management of borderline ovarian tumors – still a gray zone Indian. J Surg Oncol. 2017;8(4):607-14. DOI: 10.1007/s13193-017-0697-3 10. Каприн А.Д. Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 г. 2022. Сибирский онкологический журнал. 2023;22(5):5-13. DOI: 10.21294/1814-4861-2023-22-5-5-13 Kaprin A.D. Starinsky V.V., Shakhzadova A.O. The state of oncological care for the population of Russia in 2021-2022. Siberian Journal of Oncology. 2023;22(5):5-13. DOI: 10.21294/1814-4861-2023-22-5-5-13 (in Russian). 11. Gaurilcikas A, Gedgaudaite M, Cizauskas A et al. Performance of the IOTA ADNEX Model on Selected Group of Patients with Borderline Ovarian Tumours. Medicina (Kaunas). 2020;56(12):690. DOI: 10.3390/medicina56120690 12. Sahin H, Akdogan AI, Smith J et al Serous borderline ovarian tumours: an extensive review on MR imaging features. Brit J Radiol. 2021;94(1125):20210116. 13. Yasmeen S, Hannan A, Sheikh F et al. Borderline tumors of the ovary: A clinicopathological study. Pak J Med Sci. 2017;33(2):369-73. 14. Sun H, Chen X, Zhu T et al. Age-dependent difference in impact of fertility preserving surgery on disease-specific survival in women with stage I borderline ovarian tumors. J Ovarian Res. 2018;11:54. DOI: 10.1186/s13048-018-0423-y 15. Tal O, Ganer HH, Gluck O et al. Characteristics and prognosis of borderline ovarian tumors in pre and postmenopausal patients. Arch Gynecol Obstet. 2020;302(3):693-8. DOI: 10.1007/s00404-020-05652-w 238 16. Candotti G, Peiretti M, Mangili G et al. What women want: fertility sparing surgery in borderline ovarian tumours patients and pregnancy outcome. Eur J Surg Oncol. 2020;46(05):888-92. DOI: 10.1016/j.ejso. 2019.11.001 17. Guadagno E, Pignatiello S, Borrelli G et al. Ovarian borderline tumors, a subtype of neoplasm with controversial behavior. Role of Ki67 as a prognostic factor. Pathol Res Pract. 2019;215(11):152633. 18. Ikeda Y, Yoshihara M, Yoshikawa N, Tamauchi S et al. Is cystectomy an option as conservative surgery for young patients with borderline ovarian tumor? A multi-institutional retrospective study. Int J Gynaecol Obstet. 2022. DOI: 10.1002/ijgo.13844 19. Khiat S, Provansal M, Bottin P et al. Fertility preservation after fertility-sparing surgery in women with borderline ovarian tumours. Eur J Obstet Gynecol Reprod Biol. 2020;253:65-70. DOI: 10.1016/j.ejogrb.2020.07.053 20. Kumari S, Kumar S, Bhatla N et al. Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population. Gynecol Oncol Rep. 2021;36:100756. 21. Du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. Ann Oncol. 2016;27(Suppl 1):i20–i22. DOI: 10.1093/annonc/mdw090 22. Gotlieb WH, Chetrit A, Menczer J et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005;97(3):780-3. 23. Koskas M, Uzan C, Gouy S, Pautier P et al. Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). Hum Reprod. 2011;26(4):808-14. DOI: 10.1093/humrep/deq399 24. Koutlaki N, Dimitraki M, Zervoudis S et al. Conservative surgery for borderline ovarian tumors – emphasis on fertility preservation: A review. Chirurgia (Bucur). 2011;244:120-27. DOI: 10.1016/j.ejogrb.2019.11.016 25. Chen RF, Li J, Zhu TT et al. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience. J Ovarian Res. 2016;9(1). DOI: 10.1186/s13048-016-0226-y 26. Poncelet C, Fauvet R, Boccara J, Daraï E. Reccurence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol. 2006;13(4):565-71. 27. Johansen G, Dahm-Kähler P, Staf C et al. Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. Fertil Steril. 2021;115:157-63. 28. Jia SZ, Xiang Y, Yang JJ, Shi JH et al. Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study. Hum Reprod. 2020;35:328-39. 29. Palomba S, Zupi E, Russo T et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod. 2007;22(2):578-85. DOI: 10.1093/ humrep/del381 30. Kuji S, Harada M, Yoshioka N et al. urvival and reproductive outcomes after fertility-sparing surgery performed for borderline epithelial ovarian tumor in Japanese adolescents and young adults: results of a retrospective nationwide study. J Obstet Gynaecol Res. 2022;48(3):806-16. 31. Новикова Е.Г. Шевчук А.С., Завалишина Л.Э. Некоторые аспекты органосохраняющего лечения пограничных опухолей яичников. Российский онкологический журнал. 2010;15(4):15-20. Novikova E.G. Shevchuk A.S., Zavalishina L.E. Some aspects of organ-preserving treatment of borderline ovarian tumors. Russian Journal of Oncology. 2010;15(4):15-20. (in Russian). 32. Bourdel N, Huchon C, Abdel Wahab C et al. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation. J Gynecol Obstet Hum Reprod. 2021;50(1):101966. DOI: 10.1016/j.jogoh.2020.101966 33. Киселева М.В. Малинова И.В., Комарова Е.В. и др. Cохранение фертильности у онкологических пациентов репродуктивного возраста методом витрификации овариальной ткани. Research’n Practical Med J. 2016. Kiseleva M.V. Malinova I.V., Komarova E.V. et al. Preservation of fertility in cancer patients of reproductive age by vitrification of ovarian tissue. Research’n Practical Med J. 2016 (in Russian). 34. Fauvet R, Brzakowski M, Morice P et al. Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study. Ann Oncol. 2012;23: 1481-7. 35. Давыдова И.Ю. Карселадзе А.И., Кузнецов В.В., Ашрафян Л.А. и др. Практические рекомендации по лечению пограничных опухолей яичников. Злокачественные опухоли. 2021. DOI: 10.18027/2224-5057-2020-10-3s2-12 Davydova I.Y. Karseladze A.I., Kuznetsov V.V., Ashrafyan L.A. et al. Practical recommendations for the treatment of borderline ovarian tumors. Malignant tumors. 2021. DOI: 10.18027/2224-5057-2020-10-3s2-12 (in Russian). 36. Киселева М.В. Денисов М.С., Литвякова Е.В., Иванов С.А. и др. Сохранение фертильности у больных раком молочной железы: Обзор литературы. Клинический разбор в общей медицине. 2023;4(12):51-7. DOI: 10.47407/kr2023.4.12.00331 Kiseleva M.V. Denisov M.S., Litvyakova E.V., Ivanov S.A. et al. Fertility preservation in breast cancer patients: A literature review. Clinical analysis in general medicine. 2023;4(12):51-7. DOI: 10.47407/kr2023. 4.12.00331 (in Russian). 37. Li S, Lin H, Xie Y et al. Live births after in vitro fertilization with fertility-sparing surgery for borderline ovarian tumors: a case series and literature review. Gynecol Obstet Invest. 2019;84(5):445-54 DOI: 10.1159/000497203 38. Beiner ME, Gotlieb WH, Davidson B et al. Infertility treatment after conservative management of borderline ovarian tumor. Cancer. 2001;92:320-5. 39. Fortin A, Morice P, Thoury A, Camatte S et al. mpact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril. 2007;87(3):591. 40. Plett H, Harter P, Ataseven B et al. Fertility-sparing surgery and reproductive – outcomes in patients with borderline ovarian tumors. Gynecol Oncol. 2020;157:411–7. 41. Filippi F, Martinelli F, Somigliana E et al. Oocyte cryopreservation in two women with borderline ovarian tumor recurrence. J Assist Reprod Genet. 2020;37(5):1213-16. DOI: 10.1007/s10815-020-01733-6 42. van Leeuwen FE, Klip H, Mooij TM et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26(12):3456-65. DOI: 10.1093/humrep/der322 43. Mangili G, Somigliana E, Giorgione V, Martinelli F et al. Fertility preservation in women with borderline ovarian tumours. Cancer Treat Rev. 2016;49:13-24. DOI: 10.1016/j.ctrv.2016.06.010 44. Falcone F, Malzoni M, Carnelli M Cormio G et al. Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: analysis from the MITO14 study database. Gynecol Oncol. 2022;161:825-31. 45. Geoffron S, Lier A, de Kermadec E et al. Fertility preservation in women with malignant and borderline ovarian tumors: experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG). Gynecol Oncol. 2021;161(3):817-24. DOI: 10.1016/j.ygyno.2021.03.030 46. Gershenson DM Clinical management potential tumours of low malignancy. Best Pract. Res. Clin Obstetr Gynaecol. 2002;16(4):513-27. DOI: 10.1053/beog.2002.0308 47. Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderlin tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470(2):125-42. 48. Lertkhachonsuk AA, Buranawongtrakoon S, Lekskul N, Rermluk N et al. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors. J Obstet Gynaecol Res. 2020;46(11):2287-91. DOI: 10.1111/jog.14427 49. Nagamine M, Mikami Y. Ovarian seromucinous tumors: pathogenesis, morphologic spectrum, and clinical issues. Diagnostics (Basel). 2020;10:77. DOI: 10.3390/diagnostics10020077 50. Rasmussen ELK, Hannibal CG, Dehlendorff C et al. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study. Gynecol Oncol. 2017;144(3):571-6. 51. Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Mod Pathol. 2018;31(2):350-7. 52. Ожиганова И.Н. Морфология рака яичников в классификации ВОЗ 2013 г. Практическая онкология. 2014;15(4):143-52. Ozhiganova I.N. Morphology of ovarian cancer in the 2013 WHO classification. Practical oncology. 2014;15(4):143-52 (in Russian).